Pyxis Oncology (PYXS) Treasury Shares (2020 - 2026)
Pyxis Oncology (PYXS) posted quarterly Treasury Shares of $1.6 million for Q4 2025, down 35.49% year-over-year from $2.5 million in Q4 2024, and down 9.2% quarter-over-quarter from $1.8 million in Q3 2025.
Pyxis Oncology (PYXS) Treasury Shares (2020 - 2026) Analysis & Trends
Pyxis Oncology (PYXS) has reported Treasury Shares for 6 consecutive years, with $1.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Treasury Shares fell 35.49% year-over-year to $1.6 million; the TTM figure through Dec 2025 stood at $1.6 million (down 35.49% YoY), while the FY2025 annual figure was $1.6 million, down 35.49% from the prior year.
- Treasury Shares declined to $1.6 million in Q4 2025 per PYXS's latest filing, from $1.8 million in the prior quarter.
- Across five years, Treasury Shares topped out at $127.5 million in Q1 2021 and bottomed at $618494.0 in Q4 2021.
- Historically, Treasury Shares has averaged $21.6 million across 5 years, with a median of $3.1 million in 2024.
- Annual changes were most pronounced in 2021 — Treasury Shares surged 461.22% — and 2022, when it plunged 97.68%.
- Pyxis Oncology's Treasury Shares stood at $618494.0 in 2021, then soared by 387.54% to $3.0 million in 2022, then advanced by 20.43% to $3.6 million in 2023, then sank by 30.23% to $2.5 million in 2024, then sank by 35.49% to $1.6 million in 2025.
- Business Quant data shows PYXS's Treasury Shares at $1.6 million in Q4 2025, $1.8 million in Q3 2025, and $1.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.96 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.72 Mn |
| 10 | Pyxis Oncology | 198.37 Mn | 165.38 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.28 Mn |
| Jun 30, 2026 | 1.28 Mn |
| Dec 31, 2025 | 1.63 Mn |
| Dec 31, 2025 | 1.63 Mn |
| Sep 30, 2025 | 1.80 Mn |
| Sep 30, 2025 | 1.80 Mn |
| Jun 30, 2025 | 1.94 Mn |
| Jun 30, 2025 | 1.94 Mn |
| Mar 31, 2025 | 2.42 Mn |
| Mar 31, 2025 | 2.42 Mn |
| Dec 31, 2024 | 2.53 Mn |
| Dec 31, 2024 | 2.53 Mn |
| Sep 30, 2024 | 2.99 Mn |
| Sep 30, 2024 | 2.99 Mn |
| Jun 30, 2024 | 3.05 Mn |
| Jun 30, 2024 | 3.05 Mn |
| Mar 31, 2024 | 3.11 Mn |
| Mar 31, 2024 | 3.11 Mn |
| Dec 31, 2023 | 3.63 Mn |
| Dec 31, 2023 | 3.63 Mn |